8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 11, 2008)

Filed January 11, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on January 11, 2008, primarily to report its updated cash position as of December 31, 2007. This filing, which incorporates a press release dated January 7, 2008, provides a snapshot of the company's financial health at the close of the previous fiscal year. Investors should note that while this information is being disclosed, it is furnished and not formally "filed" under Section 18 of the Exchange Act, meaning it carries different legal implications regarding liability. The key takeaway for investors is the company's liquidity, which is crucial for funding its ongoing research and development activities in the RNA interference therapeutics space. While the 8-K does not contain detailed financial statements or operational results, the focus on cash position is a common practice for biotechnology companies during periods of development. This update allows stakeholders to assess Alnylam's runway and its ability to continue advancing its pipeline. Investors are encouraged to refer to the full press release attached as Exhibit 99.1 for the specific cash figures and any additional commentary provided by the company.

Key Highlights

  • 1Alnylam Pharmaceuticals disclosed its updated cash position for the year ended December 31, 2007, via an 8-K filing on January 11, 2008.
  • 2The disclosure was made through an attached press release dated January 7, 2008.
  • 3The primary purpose of the filing is to update investors on the company's liquidity.
  • 4The information provided is considered 'furnished' and not 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934.
  • 5This means the information is not subject to the same liabilities as formally filed information under that specific section.
  • 6The filing is relevant for assessing the company's financial runway to fund R&D efforts.

Frequently Asked Questions

The main purpose of this 8-K filing is to report Alnylam Pharmaceuticals' updated cash position as of December 31, 2007, as announced in a press release dated January 7, 2008. It provides investors with an update on the company's liquidity.

No, this 8-K filing, as described in Item 2.02, specifically focuses on the updated cash position. It does not include comprehensive financial statements or detailed operational results, but rather refers to an attached press release which contains the cash information.

When information is 'furnished' under Section 18 of the Exchange Act, it generally means it is being provided to the public but does not carry the same legal liabilities and reporting obligations as information that is formally 'filed' with the SEC. This is common for press releases and other non-material updates that companies choose to share.

The specific cash position figures for December 31, 2007, are detailed in the press release dated January 7, 2008, which is attached as Exhibit 99.1 to this Form 8-K filing. Investors should consult that document for the exact numbers.